Skip to main content
. Author manuscript; available in PMC: 2015 Jun 7.
Published in final edited form as: Hematol Oncol Clin North Am. 2009 Oct;23(5):949–v. doi: 10.1016/j.hoc.2009.07.005

Figure 2.

Figure 2

Overall survival for de novo Burkitt leukemia/lymphoma by age and therapy (hyper-CVAD with or without rituximab). Late events in the younger group treated with hyper-CVAD and rituximab were related to secondary blood dyscrasias (refer to text).